Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
$ 18.73 0.28 (1.52%) Market Cap: 21.08 Bil Enterprise Value: 37.43 Bil PE Ratio: 0 PB Ratio: 3.31 GF Score: 59/100

Q1 2024 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

May 08, 2024 / 12:00PM GMT
Release Date Price: $15.74 (+12.83%)
Operator

Hello, and welcome to the First Quarter 2024 Teva Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex. I'll be coordinating the call today.

(Operator Instructions)

I'll now hand it over to your host, Ran Meir, Head of Investor Relations. Please go ahead.

Ran Meir
Teva Pharmaceutical Industries Limited - Head of IR

Thank you, Alex, and thank you, everyone, for joining us today. We hope you have had a chance to review our Q1 results press release, along with the press release announcing positive Phase III results from olanzapine LAI trial, both issued earlier this morning. Copies of these press releases, along with the slides presented during this call are available on our website at ir.tevapharm.com.

Please review our forward-looking statements on Slide #2. Additional information on these statements and our non-GAAP financial measures can be found on our earnings release, annual SEC Forms, 10-K and 10-Q.

To begin today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's first

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot